OPTOS celebrates sales milestone at 100% Optical

Optos Celebrates Key Milestones: 25,000 Devices Installed Globally and Extensive Clinical Publications Achieved

Key Facts

• 2,500 clinical and peer-reviewed studies reached which span 235 disease states, demonstrating the clinical utility of Optos technology.
• The innovative technology from Optos offers the only single-capture ultra-widefield retinal imaging, expanding capabilities to diagnose, document, manage, and treat ocular pathology that may first present in the periphery.
• These key milestones coincide with Optos’ attendance at 100% Optical 2024 where three devices will be showcased.

Optos, a subsidiary of Nikon Corporation, is the leading retinal imaging company. Its core technology, ultra-widefield (UWF™) high-resolution digital images (optomap®) capture approximately 82% and 200◦ of the retina, something no other device can do in a single image.

Optos has also developed integrated ultra-widefield retinal imaging with image-guided Optical Coherence Tomography (OCT). Optos devices facilitate the early detection, management, and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration.

More than 2,500 published clinical studies show the long-term value of optomap imaging in detection, diagnosis, treatment planning, and patient engagement.

Optos success at 100% Optical and Ophthalmology

Optos PLC, a pioneering leader in retinal imaging technology, proudly announces a significant dual milestone achievement of over 25,000 devices installed worldwide, and the expansive collection of 2,500 clinical and peer-reviewed studies spanning 235 disease states. This announcement coincides with the 100% Optical 2024 conference currently taking place in London, UK, where Optos is showcasing their unique technology. For more than 30 years, Optos has had a positive impact on the standard of retinal imaging technology and supported the advancement of patient care.

“This remarkable double milestone reflects the unwavering commitment that Optos has had to innovation and excellence in providing the best, clinically relevant technology available, since our inception. The ongoing growth and recognition of the robust body of clinical research efforts underscores the dedication of our team to continue improving patient outcomes and driving development in ophthalmic care,” said Chief Executive Officer, Robert Kennedy. “We extend our sincerest gratitude to our customers for their continued trust and support. Their feedback and partnership are invaluable as we strive to make retinal imaging more patient-friendly and accessible while empowering clinicians to deliver exceptional care.”

Optos, the only provider of single-capture ultra-widefield retinal imaging, has redefined the standard for comprehensive imaging beyond traditional constraints, crucial for diagnosing and managing a wide range of eye conditions that otherwise may go undetected and undiagnosed. With nine imaging modalities available across all device platforms, including the recent addition of optomap colour rgb, natural colour imaging modality and optomap blue fundus autofluorescence, Optos technology offers unparalleled diagnostic capabilities. Its combined imaging devices integrate ultra-widefield retinal imaging with optomap-guided OCT, providing clinicians with comprehensive insights into retinal health.

Consistently expanding the continuum of care, Optos technology seamlessly integrates into a variety of healthcare settings from telehealth to retina. With continued prioritisation for eyecare providers on device ease of use and productivity, Optos technology streamlines workflow and enhances practice efficiency without compromising quality. The commitment to patient and user-friendly solutions continues to drive modernisation and excellence in ophthalmic imaging, ultimately improving patient outcomes and enhancing practice efficiency worldwide.

At 100% Optical, Optos will be showcasing three devises at booth M110 and holding a live demonstration to showcase the benefits Optos technology can bring. Additionally, Vasuki Sivagnanavel, Consultant Ophthalmic Surgeon, The Royal Eye Unit, Kingston Hospital, presented on the main stage on ‘Diagnostic insights with retinal ultra-widefield multimodal imaging,’ discussing the benefits of ultra-widefield imaging to aid diagnosis and management of retinal abnormalities.

For more information about Optos and its industry-leading retinal imaging technology, visit the Optos website at www.optos.com.